In intermediate risk prostate cancer, fewer weeks of hormone therapy before radiation reduces side effects

A shorter course of androgen suppression therapy prior to radiation therapy, when compared to a longer course of androgen suppression therapy, yields favorable outcomes and fewer adverse effects for intermediate-risk prostate cancer patients, according to research presented today at the American Society for Radiation Oncology's (ASTRO) 55th Annual Meeting. The study confirmed a disease-specific-survival (DSS) rate of 95 percent when patients received fewer weeks of neoadjuvant (NEO) total androgen suppression (TAS)...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news